| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 16 Nov 2026 | SCHEDULE 13G/A |
| 16 Nov 2026 | SCHEDULE 13G/A |
| 16 Nov 2026 | 424B5 |
| 16 Nov 2026 |
8-K: Entry into a Material Definitive Agreement
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: |
| 16 Nov 2026 | SCHEDULE 13G |
| 13 Nov 2026 | SCHEDULE 13G/A |
| 13 Nov 2026 | FWP |
| 09 Nov 2026 | 10-Q |
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition
First patient dosed in Phase 1b of DUET study evaluating SZN-8141 in patients with diabetic macular edema |
| 06 Nov 2026 | SCHEDULE 13D/A |
| 22 Oct 2026 |
Form 4: Column Group Iii GP, Lp, 10% owner and 6 others
Received 1,551,724 shares by exercise ($18M) · Acquired 775,862 Series E Common Warrants (In/At-money Exercise) |
| 22 Oct 2026 | SCHEDULE 13D/A |
| 22 Oct 2026 |
Form 4: Kutzkey Tim, Director
Received 1,551,724 shares by exercise ($18M) · Acquired 775,862 Series E Common Warrants (In/At-money Exercise) |
| 20 Oct 2026 |
8-K: Results of Operations and Financial Condition; Unregistered Sales of Equity Securities
Proceeds strengthen balance sheet and provide expected cash runway into 2029 to advance SZN-8141 and SZN-8143 |
| 07 Oct 2026 | SCHEDULE 13G/A |
| 02 Oct 2026 |
8-K: Other Events
On October 2, 2026, Surrozen, Inc. (Surrozen) announced U.S. Food and Drug Administration (FDA) clearance of our Investigational New Drug (IND) application for SZN-8141, enabling us to advance the program into clinical development. The I... |
| 01 Oct 2026 | SCHEDULE 13G |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G/A |
Loading...